TABLE 1.
Risk of bias assessments for all selected studies using the Joanna Briggs Institute (JBI) critical appraisal checklist for studies reporting prevalence data
| Study | Q1: Was the sample frame appropriate to address the target population? | Q2: Were study participants sampled in an appropriate way? | Q3: Was the sample size adequate? | Q4: Were the study subjects and the setting described in detail? | Q5: Was the data analysis conducted with sufficient coverage of the identified sample? | Q6: Were valid methods used for the identification of the condition? | Q7: Was the condition measured in a standard, reliable way for all participants? | Q8: Was there appropriate statistical analysis? | Q9: Was the response rate adequate, and if not, was the low response rate managed appropriately? | Overall risk of bias |
|---|---|---|---|---|---|---|---|---|---|---|
| Agrawal et al. 2021 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Altuntas et al. 2020 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Averbuch et al. 2021 | Y | Y | N * | Y | N ∆ | Y | Y | Y | Y | Low |
| Bailén et al. 2020 | Y | Y | Y | Y | Y | U ¥ | U ¥ | Y | Y | Low |
| Basquiera et al. 2021 | Y | Y | N * | Y | N Ω | Y | Y | Y | Y | Low |
| Camargo et al. 2021 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Chari et al. 2020 | Y | Y | Y | N ◊ | N Ψ , γ | Y | Y | Y | Y | Low |
| Coll et al. 2020 | Y | Y | Y | N ◊ | U □ | Y | Y | Y | Y | Low |
| De Ramón et al. 2020 | Y | Y | Y | N ◊ | U □ | Y | Y | Y | Y | Low |
| Dwabe et al. 2021 | Y | Y | N * | Y | N † | Y | Y | Y | Y | Low |
| Fakih et al. 2021 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Faura et al. 2020 | Y | Y | N * | N ◊ | N ∆ , Ω | Y | Y | N/A ○ | Y | Mod |
| Fox et al. 2020 | Y | Y | N * | N ◊ | N γ | Y | Y | Y | Y | Mod |
| Haroon et al. 2020 | Y | Y | N * | Y | Y | Y | Y | N/A ○ | Y | Low |
| Jimenez‐Kurlander et al. 2020 | Y | Y | N * | N ◊ | N ∆ , Ω | U θ | Y | N/A ○ | Y | High |
| Kanellopoulos et al. 2020 | Y | Y | N * | Y | Y | Y | Y | N/A ○ | Y | Low |
| Karatas et al. 2021 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Kebudi et al. 2020 | Y | Y | N * | N ◊ | N ∆ | Y | Y | N/A ○ | Y | Mod |
| Ljungman et al. 2021 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Lucchini et al. 2021a | Y | Y | N * | Y | N ∆ , Ω | Y | Y | N/A ○ | Y | Mod |
| Lucchini et al. 2021b | Y | Y | Y | Y | N Ω | Y | Y | Y | Y | Low |
| Lupo‐Stanghellini et al. 2021 | Y | Y | N * | Y | N Ω | Y | Y | N/A ○ | Y | Mod |
| Machado et al. 2020 | Y | Y | N * | N ◊ | Y | Y | Y | Y | Y | Low |
| Malard et al. 2020 | Y | Y | N * | Y | Y | Y | Y | N/A ○ | Y | Low |
| Mico et al. 2020 | Y | Y | N * | Y | N Ω | Y | Y | Y | Y | Low |
| Mushtaq et al. 2021 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Passamonti et al. 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Pinana et al. 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Shah et al. 2020 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Sharma et al. 2021 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Low |
| Sultan et al. 2020 | Y | Y | N * | Y | N ∆ , Ω | Y | Y | N/A ○ | Y | Mod |
| Tailor et al. 2020 | Y | Y | N * | Y | N γ | U ¥ | U ¥ | N/A ○ | Y | Mod |
| Varma et al. 2020 | Y | Y | N * | Y | Y | Y | Y | Y | Y | Low |
| Vicent et al. 2020 | Y | Y | N * | Y | N ∆ , Ω | Y | Y | N/A ○ | Y | Mod |
| Wang et al. 2020 | Y | Y | N * | N ◊ | N Ψ , γ | Y | Y | Y | Y | Mod |
| Xhaard et al. 2021 | Y | Y | N * | Y | N Ω | Y | Y | Y | Y | Low |
Abbreviations: HCT, haematopoietic cell transplantation; N, no; N/A, not applicable; SCT, stem cell transplantation; U, unclear; Y, yes.
Study sample size lower than estimated sample size required using estimated mortality risk of 25%, precision 0.1.
Insufficient description of patient/HCT treatment information.
Insufficient patient/treatment information provided to determine coverage.
Only HCT patients <50 years old included.
Descriptive report no meaningful statistical analysis performed.
Only allogeneic SCT recipients included.
Only multiple myeloma patients included.
Only autologous SCT recipients included.
Use of SARS‐CoV‐2 IgG positivity only as the inclusion criteria may introduce selection bias towards survivors of COVID‐19 infection.
Only one auto‐HCT recipient included.
Diagnostic criteria for COVID‐19 infection not provided.